The DOI matches its Crossref record.
Differential Complementation of Bcr-Abl Point Mutants with c-Myc
Abstract
A complementation strategy was developed to define the signaling pathways activated by the Bcr-Abl tyrosine kinase. Transformation inactive point mutants of Bcr-Abl were tested for complementation with c-Myc. Single point mutations in the Src-homology 2 (SH2) domain, the major tyrosine autophosphorylation site of the kinase domain, and the Grb-2 binding site in the Bcr region impaired the transformation of fibroblasts by Bcr-Abl. Hyperexpression of c-Myc efficiently restored transformation activity only to the Bcr-Abl SH2 mutant. These data support a model in which Bcr-Abl activates at least two independent pathways for transformation. This strategy may be useful for discerning signaling pathways activated by other oncogenes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationReflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 879
Proteins of the Myc Network: Essential Regulators of Cell Growth and Differentiation
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60353-x · Cited by 779
Skorski, T., Bellacosa, A., Nieborowska‐Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6151 · Cited by 567
“, 1993); the ΔSH2 BCR/ABL mutant which lacks the entire SH2 domain (aa 1030–1120) (Ilaria and Van Etten, 1995); the SH2 FLVRES motif mutant R1053L (FLVLES) which, like the ΔSH2 mutant, fails to bind motifs containing phosphorylated tyrosines (Afar et al., 1994); the ΔSH3 BCR/ABL mutant which lacks the entire SH3 domai…”
BackgroundInfluentialDirect induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27
Bouchard, C. (1999) · The EMBO Journal · doi:10.1093/emboj/18.19.5321 · Cited by 502
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
Bowman, T., Broome, M. A., Sinibaldi, D., Wharton, W., Pledger, W. J., Sedivy, J. M., Irby, R., Yeatman, T., Courtneidge, S. A., & Jove, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131568898 · Cited by 488
The BCR-ABL Story: Bench to Bedside and Back
Wong, S., & Witte, O. N. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104753 · Cited by 399
Self-citationThe Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Raitano, A. B., Halpern, J. R., Hambuch, T. M., & Sawyers, C. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11746 · Cited by 394
Self-citationA requirement for NF-kappa B activation in Bcr-Abl-mediated transformation
Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., & Baldwin Jr., A. S. (1998) · Genes & Development · doi:10.1101/gad.12.7.968 · Cited by 392
Function of the c-Myc Oncogenic Transcription Factor
Dang, C. V., Resar, L. M. S., Emison, E., Kim, S., Li, Q., Prescott, J. E., Wonsey, D., & Zeller, K. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4686 · Cited by 379
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Self-citationOligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia
Golub, T. R., Goga, A., Barker, G. F., Afar, D. E. H., McLaughlin, J., Bohlander, S. K., Rowley, J. D., Witte, O. N., & Gilliland, D. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4107 · Cited by 324
Self-citationMouse disabled (mDab1): a src binding protein implicated in neuronal development
Howell, B. W., Gertler, F. B., & Cooper, J. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.1.121 · Cited by 287
Cortez, D., Kadlec, L., & Pendergast, A. M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5531 · Cited by 267
Myc Roles in Hematopoiesis and Leukemia
Delgado, M. D., & Leon, J. (2010) · Genes & Cancer · doi:10.1177/1947601910377495 · Cited by 255
Sawyers, C. L., McLaughlin, J., & Witte, O. N. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.307 · Cited by 253
Self-citationThe c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Albajar, M., Gómez-Casares, M. T., Llorca, J., Mauleon, I., Vaqué, J. P., Acosta, J. C., Bermúdez, A., Donato, N., Delgado, M. D., & León, J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0356 · Cited by 62
Metadata
- Authors
- Afar, D. E. H., Goga, A., McLaughlin, J., Witte, O. N., & Sawyers, C. L.
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 424-426
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2083091935
- Cited by
- 184
- References
- 0
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.